NIAID: Three-Dose Hepatitis B Vaccine Regimen Protects People with HIV

NIAID: Three-Dose Hepatitis B Vaccine Regimen Protects People with HIV

Updated: 3 months, 7 days, 19 hours, 45 minutes, 29 seconds ago

The National Institute of Allergy and Infectious Diseases (NIAID) announced that a three-dose course of the hepatitis B vaccine, HEPLISAV-B, fully protects adults living with HIV who have never been vaccinated against, or infected with, the hepatitis B virus (HBV), according to study findings presented on Friday, Oct. 21, at the Infectious Diseases (ID) Week conference in Washington, D.C. The NIAID, part of the National Institutes of Health, is sponsoring the ongoing Phase 3 ACTG A5379 clinical study.


HBV is spread primarily through sexual contact and through the sharing of contaminated needles. It can cause chronic hepatitis B infection and lead to progressive liver disease. People living with HIV, including those who are taking antiretroviral therapy, are at greater risk of liver-related illness and death when co-infected with HBV.


NIAID representatives said researchers tested a three-dose course of HEPLISAV-B, made by Dynavax Technologies, Corp., among 68 adults living with HIV at 38 sites in the United States, South Africa, and Thailand. Nearly all (98.5 percent) of the study participants developed protective antibodies against HBV. The international study, which continues to examine the effects of the two-dose HEPLISAV-B and a three-dose regimen of another hepatitis B vaccine, is expected to complete vaccinations in March 2023.


Earlier this year, Norwood News reported on the alarming resurgence of HIV, which caused the AIDs epidemic in the 1980s, in The Bronx and throughout New York City, as well as on ongoing efforts to address and curtail this latest trend, particularly among the LGBTQIA community. Bronx Borough President Vanessa Gibson said at the time, “Transgender women are estimated to be 49 times more likely to be living with HIV, compared to the general population.”


She added, “Additionally, The Bronx had the second highest number of new HIV diagnoses in 2020, and the highest percentage of HIV deaths.” Gibson was citing figures compiled by New York City Department of Health & Mental Hygiene (DOHMH).


Meanwhile, as also reported, the world’s first HIV-positive to HIV-positive heart transplant was performed at Montefiore Health System in July of this year.


Representatives at the ID conference said they were thrilled to have Dr. Anthony Fauci join them at the Edward H. Kass Lecture, with a special tribute being planned for the retiring doctor who became the face of the COVID-19 pandemic, and who continues to bear the brunt of some people’s anger over various federal, pandemic-related policy decisions taken since 2020.   


Meanwhile, as reported by The Guardian, Fauci, America’s top infectious disease expert, has warned against prematurely declaring victory over the pandemic, not only due to short-term needs but because long COVID represents an “insidious” public health emergency for millions of people. U.S. President Joe Biden recently, and controversially, declared the pandemic was over in September 2022. 




Welcome to the Norwood News, a bi-weekly community newspaper that primarily serves the northwest Bronx communities of Norwood, Bedford Park, Fordham and University Heights. Through our Breaking Bronx blog, we focus on news and information for those neighborhoods, but aim to cover as much Bronx-related news as possible. Founded in 1988 by Mosholu Preservation Corporation, a not-for-profit affiliate of Montefiore Medical Center, the Norwood News began as a monthly and grew to a bi-weekly in 1994. In September 2003 the paper expanded to cover University Heights and now covers all the neighborhoods of Community District 7. The Norwood News exists to foster communication among citizens and organizations and to be a tool for neighborhood development efforts. The Norwood News runs the Bronx Youth Journalism Heard, a journalism training program for Bronx high school students. As you navigate this website, please let us know if you discover any glitches or if you have any suggestions. We’d love to hear from you. You can send e-mails to or call us anytime (718) 324-4998.